Literature DB >> 19389137

Barriers to satisfactory migraine outcomes. What have we learned, where do we stand?

Marcelo Bigal1, Abouch Valenty Krymchantowski, Richard B Lipton.   

Abstract

Barriers to optimal migraine care have traditionally been divided into a number of categories: under-recognition and underconsultation by migraine sufferers; underdiagnosis and undertreatment by health care professionals; lack of follow-up and treatment optimization. These "traditional" barriers have been recognized and addressed for at least 15 years. Epidemiologic studies suggest that consultation, diagnosis, and treatment rates for migraine have improved although many migraine sufferers still do not get optimal treatment. Herein, we revisit the problem, review areas of progress, and expand the discussion of barriers to migraine care. We hypothesize that the subjective nature of pain and difficulty in communicating it contributes to clinical and societal barriers to care. We then revisit some of the traditional barriers to care, contrasting rates of recognition, diagnosis, and treatment over the past 15 years. We follow by addressing new barriers to migraine care that have emerged as a function of the knowledge gained in this process.

Entities:  

Mesh:

Year:  2009        PMID: 19389137     DOI: 10.1111/j.1526-4610.2009.01410.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  10 in total

1.  SPARTACUS: underdiagnosis of chronic daily headache in primary care.

Authors:  G Giannini; V Favoni; S Bauleo; T Ferrante; G Pierangeli; F Albani; M L Bacchi Reggiani; A Baruzzi; P Cortelli; S Cevoli
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 2.  Guideline for primary care management of headache in adults.

Authors:  Werner J Becker; Ted Findlay; Carmen Moga; N Ann Scott; Christa Harstall; Paul Taenzer
Journal:  Can Fam Physician       Date:  2015-08       Impact factor: 3.275

Review 3.  Nutraceuticals and Behavioral Therapy for Headache.

Authors:  Rebecca Barmherzig; Thilinie Rajapakse
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-10       Impact factor: 5.081

4.  Psychological evaluation of a primary headache patient.

Authors:  Dana P Turner; Timothy T Houle
Journal:  Pain Manag       Date:  2013-01-01

5.  The risk of breast cancer associated with specific patterns of migraine history.

Authors:  Sarah J Lowry; Kathleen E Malone; Kara L Cushing-Haugen; Christopher I Li
Journal:  Cancer Causes Control       Date:  2014-10-31       Impact factor: 2.506

6.  Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders.

Authors:  Abouch Valenty Krymchantowski; Carla da Cunha Jevoux; Marcelo E Bigal
Journal:  J Headache Pain       Date:  2011-10-19       Impact factor: 7.277

7.  Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries.

Authors:  Mattias Linde; Timothy J Steiner; Dan Chisholm
Journal:  J Headache Pain       Date:  2015-02-18       Impact factor: 7.277

8.  Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Authors:  David Yarnitsky; David W Dodick; Brian M Grosberg; Rami Burstein; Alon Ironi; Dagan Harris; Tamar Lin; Stephen D Silberstein
Journal:  Headache       Date:  2019-05-09       Impact factor: 5.887

9.  More Attacks and Analgesic Use in Old Age: Self-Reported Headache Across the Lifespan in a German Sample.

Authors:  Britta Müller; Thomas Dresler; Charly Gaul; Änne Glass; Tim P Jürgens; Peter Kropp; Ruth Ruscheweyh; Andreas Straube; Stefanie Förderreuther
Journal:  Front Neurol       Date:  2019-10-17       Impact factor: 4.003

10.  Use of outpatient medical care by headache patients in Germany: a population-based cross-sectional study.

Authors:  Britta Müller; Thomas Dresler; Charly Gaul; Tim Jürgens; Peter Kropp; Anna Rehfeld; Olaf Reis; Ruth Ruscheweyh; Andreas Straube; Stefanie Förderreuther
Journal:  J Headache Pain       Date:  2020-05-11       Impact factor: 7.277

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.